BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G.
Shi R, et al. Among authors: ludkovski o.
Lung Cancer. 2020 Aug;146:78-85. doi: 10.1016/j.lungcan.2020.05.018. Epub 2020 May 21.
Lung Cancer. 2020.
PMID: 32521388